MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/pediatric18030077

Медицинская библиотека · Pediatric reports · 2026

Efficacy and Safety of Umifenovir (Arbidol) in Children with Influenza-like Illnesses: A Systematic Review and Meta-Analysis.

Bulgakova Vilya, Poromov Artem, Leneva Irina, Pshenichnaya Natalia

СтатьяОбзорПеревод в очереди

Аннотация

Background

Pediatric influenza-like illness (ILI) represents a major global health burden. However, international treatment guidelines lack robust evidence specific to children. Umifenovir (Arbidol) is a broad-spectrum antiviral approved for pediatric use in several countries, but clinical data are fragmented and regionally limited.

Methods

A comprehensive search of PubMed, Russian (RSCI, national archives, regulatory documents), and Chinese (CNKI) databases was conducted for pediatric randomized controlled trials (RCTs) and non-randomized trials comparing umifenovir to symptomatic therapy (ST) or oseltamivir. Risk of bias was assessed using the RoB 2 tool for RCTs, and ROBINS-I for non-RCTs. Outcomes included the duration of fever and other symptoms, prophylactic efficacy, and adverse events. Random-effects models were used (Hartung-Knapp-Sidik-Jonkman approach). The review was not registered.

Results

We included 16 therapeutic and eight prophylactic trials enrolling approximately 4700 and 2000 children, respectively. Compared with ST, umifenovir reduced the duration of fever (MD -1.41 days, 95% CI: -1.78 to -1.05), cough (-1.15 days, 95% CI: -1.50 to -0.79), and hospitalization. The complication risk decreased (RR 0.34, 95% CI: 0.23-0.51). For prophylaxis, umifenovir reduced the risk of ILI (RR 0.68, 95% CI: 0.54-0.87) and laboratory-confirmed influenza (RR 0.41, 95% CI: 0.29-0.59). Adverse events were generally mild and did not differ significantly from ST or oseltamivir (RR 0.78, 95% CI: 0.51-1.20).

Conclusions

Umifenovir may reduce symptom duration, complications, and infection risk in pediatric ILI, with a favorable safety profile. However, the overall certainty of evidence is limited by the age of the studies, geographic restriction, and methodological quality.

Для цитирования: Bulgakova Vilya, Poromov Artem, Leneva Irina, Pshenichnaya Natalia. Efficacy and Safety of Umifenovir (Arbidol) in Children with Influenza-like Illnesses: A Systematic Review and Meta-Analysis.. Pediatric reports. 2026. DOI: 10.3390/pediatric18030077.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.